Almirall S.A. | Ownership

Companies that own Almirall S.A.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Santander Asset Management SA SGIIC
3,041,623
1.75%
607,404
0.6%
03/31/2018
Norges Bank Investment Management
2,513,177
1.45%
-1,218,028
0.01%
12/31/2017
BBVA Asset Management SA SGIIC
2,401,900
1.38%
2,210,160
0.4%
04/30/2018
Générali Investments Europe SpA SGR (France)
2,179,068
1.25%
-22,000
0.86%
08/31/2018
The Vanguard Group, Inc.
1,511,417
0.87%
9,246
0%
07/31/2018
Mutuactivos SA SGIIC
1,442,399
0.83%
180,817
2.9%
03/31/2018
Adelphi Capital LLP
1,394,823
0.8%
-411,766
2.34%
07/11/2017
Sabadell Asset Management SA SGIIC Sociedad Unipersonal
1,275,254
0.73%
247,590
0.36%
03/31/2018
Renta 4 Gestora SGIIC SA
1,160,612
0.67%
-16,855
1.05%
03/31/2018
Magallanes Value Investors SA SGIIC
976,782
0.56%
91,865
1.61%
03/31/2018

About Almirall

View Profile
Address
Ronda General Mitre, 151
Barcelona Catalonia 08022
Spain
Employees -
Website http://www.almirall.com
Updated 07/08/2019
Almirall SA engages in the development, manufacture, storage, commercialization and sale of pharmaceutical and cosmetic products, as well as of the raw materials used in production. The company operates through the following segments: Marketing through Own Network, Marketing by Licensees, Research and Development Activity, Therapeutic Area of Dermatology in the United States, and Corporate Management and Results not assigned to Other Segments. Its products include treatments for respiratory, autoimmune, dermatological and gastrointestinal diseases.